Open Access Articles- Top Results for CX-516


Systematic (IUPAC) name
Clinical data
Pharmacokinetic data
Half-life 45 minutes
154235-83-3 7pxY
PubChem CID 148184
ChemSpider 130635 7pxY
UNII Z5QU38B4V9 7pxY
KEGG C13675 7pxY
ChEMBL CHEMBL136800 7pxY
Chemical data
Formula C14H15N3O
241.289 g/mol
 14pxY (what is this?)  (verify)

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

See also


Lua error in package.lua at line 80: module 'Module:Buffer' not found.